Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,911.10
    +580.70 (+1.15%)
     

  • CMC Crypto 200

    1,335.71
    -60.82 (-4.36%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Mantle Cell Lymphoma Therapeutics Market to Reach $3.29 Billion by 2028 with Innovations in Targeted Therapies

Research and Markets
·3-min read
Company Logo
Company Logo

Dublin, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The "Mantle Cell Lymphoma Therapeutics Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.

The latest market research report indicates significant growth within the mantle cell lymphoma therapeutics sector, projecting an increase to $3.29 billion by 2028. The report highlights key drivers such as advances in targeted treatment options, the rising prevalence of mantle cell lymphoma, and the growing implementation of telemedicine in healthcare.

Mantle Cell Lymphoma Therapeutics Market: Robust Growth Projected

Current industry analysis reveals strong growth trends, with the market value anticipated to climb from $2.45 billion in 2024 to $3.29 billion by 2028. The acceleration is powered by innovative treatments and the rising incidence of mantle cell lymphoma. As a rare form of non-Hodgkin lymphoma, MCL affects the lymphatic system, and the need for effective management and treatment options is more critical than ever.

ADVERTISEMENT

Telemedicine: A Catalyst for Market Expansion

The surge in telemedicine services, offering remote healthcare consultations via telecommunication technology, is set to enhance patient care within the mantle cell lymphoma therapeutics market. These services are making it easier for patients to access specialized care, leading to improved treatment outcomes.

Innovations and Approvals: Shaping the Market Landscape

Major players in the industry are focusing on the development of targeted therapy drugs. Notable FDA approvals for kinase inhibitors by leading pharmaceutical companies have introduced new, effective treatments for patients with MCL. This class of drugs is designed to disrupt specific kinase enzymes, integral to the progression of cancer cells.

Acquisitions to Strengthen Product Portfolios

Strategic acquisitions by global pharmaceutical companies aim to bolster their offerings in the mantle cell lymphoma therapeutics market. These investments are critical to developing advanced treatments that address the complexities of MCL.

Global Market Analysis

North America emerged as the largest region for the market in 2023. Comprehensive coverage of other critical regions includes Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Treatment Modalities Defining the Market

  • Combination therapy and monotherapy represent the primary categories within the market.

  • Drugs utilized in these modalities function through various pathways like Bruton tyrosine kinase inhibitors, alkylating agents, and monoclonal antibodies, delivered through oral and parenteral routes.

  • Hospitals, research institutes, and other healthcare settings remain key applications for these therapeutics.

The detailed mantle cell lymphoma therapeutics market reports seek to offer a comprehensive analysis, as entities continue to generate significant revenues from transformative drugs within this medical sector. The studies are focused on providing a granular insight into mantle cell lymphoma therapeutics, comprising usage statistics, regional shares, participating competitors, and the evolving market dynamics.

For further insights into the mantle cell lymphoma therapeutics market and to understand the critical trends shaping this industry's future, explore the in-depth research report, which presents an overview of current and future market scenarios.

A selection of companies mentioned in this report includes

  • AstraZeneca plc

  • Celgene Corporation

  • Johnson & Johnson Consumer Inc.

  • Takeda Pharmaceutical Company Limited

  • Bayer Aktiengesellschaft

  • Eli Lilly and Company

  • Amgen Inc.

  • GlaxoSmithKline plc

  • Kite Pharma Inc.

  • Gilead Sciences Inc.

  • AbbVie Inc.

  • Bristol-Myers Squibb Company

  • Novartis AG

  • Merck & Co. Inc.

  • Massive Bio Inc.

  • Juno Therapeutics Inc.

  • Nurix Therapeutics Inc.

  • Janssen Biotech Inc.

  • TG Therapeutics Inc.

  • F. Hoffmann-La Roche AG

  • Astex Pharmaceuticals Inc.

  • Astellas Pharma Inc.

  • BeiGene Ltd.

  • Daiichi Sankyo Company Limited

  • Eisai Co. Ltd.

  • Exelixis Inc.

  • Hutchison China MediTech Limited

  • Incyte Corporation

  • Ionis Pharmaceuticals Inc.

  • KalVista Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/aggu7d

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900